Follow Us
954-421-3200

NEW MELANOMA DRUG LOOKS PROMISING FOR STAGE III AND IV MELANOMA PATIENTS

51% Of Patients Benefited In Phase II Trial.

Forbes (10/30, Fortonbury) reports that in a study published in Annals of Surgical Oncology, a new cancer drug, PV-10, 51% of stage III and IV melanoma patients benefited during a phase II trial, and achieved total cancer disappearance in 26%. In addition, the response tended to be both rapid and dramatic, with a high rate of response. This drug is extremely promising and is much needed for the treatment of advanced melanoma. Provectus Biopharmaceuticals, Inc. is the company that engineered PV-10.

Dr. Bader
About the Author
Is an Ivy-League trained physician and surgeon who is a board-certified Dermatologist & Mohs' Surgeon. Aside from having training in Internal Medicine and Dermatology, Dr. Bader completed a fully accredited fellowship in Cosmetic Surgery under the auspices of the American Academy of Cosmetic Surgery. He moved to South Florida in June 1999. Shortly thereafter, he formed R.S.B. Dermatology in Deerfield Beach, FL.